A&R: 接受甲氨蝶呤治疗的类风湿关节炎患者合用Tofacitinib(CP-690,550)的临床随机研究
2013-05-03 A&R dxy
来自荷兰莱顿大学医学中心的Desiree van der Heijde等人进行了一项研究,该项为期24周的三期研究的目的是检验Tofacitinib对甲氨蝶呤(MTX)疗效不佳的类风湿关节炎(RA)患者的关节结构的保护的作用。数据来源于第12周的中期分析报告。研究结果在线发布在2013年3月的ARTHRITIS & RHEUMATISM(关节炎与风湿病)上。研究者发现,接受MTX治疗的RA
来自荷兰莱顿大学医学中心的Desiree van der Heijde等人进行了一项研究,该项为期24周的三期研究的目的是检验Tofacitinib对甲氨蝶呤(MTX)疗效不佳的类风湿关节炎(RA)患者的关节结构的保护的作用。数据来源于第12周的中期分析报告。研究结果在线发布在2013年3月的ARTHRITIS & RHEUMATISM(关节炎与风湿病)上。研究者发现,接受MTX治疗的RA患者,合用tofacitinib能抑制关节结构破坏,并降低疾病活动度。
研究者进行了一项双盲,平行,安慰剂对照的研究,接受背景MTX治疗的患者随机分组为4:4:1:1,分别接受如下治疗:tofacitinib 5mg 每天两次、tofacitinib 10mg 每天两次、tofacitinib的安慰剂 5mg 每天两次或placebo的安慰剂 10mg 每天两次。在3个月时,接受安慰剂治疗的无反应患者以盲态升级为上述的tofacitinib治疗,剩余的接受安慰剂治疗的患者继续安慰剂治疗6个月。以递减的过程分析四个主要疗效终点。
研究结果如下,在6个月时,依据美国大学风湿病协会20 %改善标准,tofacitinib 5mg 每日两次和tofacitinib 10mg 每日两次组的缓解率高于安慰剂组(分别是51.5%和61.8% vs 25.3%,p均<0.0001)。在6个月时,tofacitinib 5mg 每天两次和tofacitinib 10mg 每天两次组的修订总Sharp/van der Heijde评分的最小二乘均数(LSM)的变化分别是0.12和0.06,vs 0.47(安慰剂组)(分别是P=0.079,P < 0.05)。在3个月时,tofacitinib 5mg 每天两次和tofacitinib 10mg 每天两次组的健康调查问卷残疾指数积分的LSM变化分别是-0.40(以递减过程显著性未宣布)和-0.54(P < 0.0001),vs -0.15(安慰剂组)。在6个月时,tofacitinib 5mg 每天两次和tofacitinib 10mg 每天两次组的缓解率(依据包括血沉的28个关节的四个变量的疾病活动积分<2.6 )分别是7.2%(以递减过程显著性未宣布)和16%(P < 0.0001)。安全性和以前的研究结果一致。
研究发现,来自12月的中期分析数据证实,接受MTX治疗的RA患者,合用tofacitinib能抑制关节结构破坏,并降低疾病活动度。
与类风湿相关的拓展阅读:
- ARD:紫外线暴露可减少女性罹患类风湿关节炎风险
- Ann Rheum Dis:日光浴或预防类风湿关节炎
- Rheumatology:类风湿关节炎患者整体肿瘤罹患风险高
- Lancet:依那西普维持治疗可控制类风湿关节炎疾病活动
- Arthritis Rheum:类风湿关节炎患者 THA后易脱臼,TKA后易感染
- FDA批准第一个治疗类风湿关节炎口服生物制剂Xeljanz 更多信息请点击:有关类风湿更多威廉亚洲官网
Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study.
OBJECTIVE
The purpose of this 24-month phase III study was to examine structural preservation with tofacitinib in patients with rheumatoid arthritis (RA) with an inadequate response to methotrexate (MTX). Data from a planned 12-month interim analysis are reported.
METHODS
In this double-blind, parallel-group, placebo-controlled study, patients receiving background MTX were randomized 4:4:1:1 to tofacitinib at 5 mg twice daily, tofacitinib at 10 mg twice daily, placebo to tofacitinib at 5 mg twice daily, and placebo to tofacitinib at 10 mg twice daily. At month 3, nonresponder placebo-treated patients were advanced in a blinded manner to receive tofacitinib as indicated above; remaining placebo-treated patients were advanced at 6 months. Four primary efficacy end points were all analyzed in a step-down procedure.
RESULTS
At month 6, response rates according to the American College of Rheumatology 20% improvement criteria for tofacitinib at 5 mg and 10 mg twice daily were higher than those for placebo (51.5% and 61.8%, respectively, versus 25.3%; both P < 0.0001). At month 6, least squares mean (LSM) changes in total modified Sharp/van der Heijde score for tofacitinib at 5 mg and 10 mg twice daily were 0.12 and 0.06, respectively, versus 0.47 for placebo (P = 0.0792 and P ≤ 0.05, respectively). At month 3, LSM changes in the Health Assessment Questionnaire disability index score for tofacitinib at 5 mg and 10 mg twice daily were -0.40 (significance not declared due to step-down procedure) and -0.54 (P < 0.0001), respectively, versus -0.15 for placebo. At month 6, rates of remission (defined as a value <2.6 for the 4-variable Disease Activity Score in 28 joints using the erythrocyte sedimentation rate) for tofacitinib at 5 mg and 10 mg twice daily were 7.2% (significance not declared due to step-down procedure) and 16.0% (P < 0.0001), respectively, versus 1.6% for placebo. The safety profile was consistent with findings in previous studies.
CONCLUSION
Data from this 12-month interim analysis demonstrate that tofacitinib inhibits progression of structural damage and improves disease activity in patients with RA who are receiving MTX.
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
#CIT#
51
#类风湿关节炎患者#
42
#随机研究#
58
#FAC#
58
#TOF#
49
#Tofacitinib#
53
#关节炎#
54
#类风湿#
48
#风湿关节炎#
46